New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis

June 2020 | Volume 19 | Issue 6 | Original Article | 602 | Copyright © June 2020

Published online May 8, 2020

Lawrence F. Eichenfield MD,ª Emil A. Tanghetti MD,b Eric Guenin PharmD PhD MPH,c Gina Martin MOT,d Radhakrishnan Pillai PhDd

ªDepartments of Dermatology and Pediatrics; University of California, San Diego School of Medicine and Rady Children's Hospital, San Diego, CA bCenter for Dermatology and Laser Surgery, Sacramento, CA cOrtho Dermatologics*, Bridgewater, NJ dBausch Health US, LLC*, Petaluma, CA *Bausch Health US, LLC is an affiliate of Bausch Health Companies Inc. Ortho Dermatologics is a division of Bausch Health US, LLC.

9. Skroza N, Tolino E, Mambrin A, et al. Adult acne versus adolescent acne: A retrospective study of 1,167 patients. J Clin Aesthet Dermatol. 2018;11(1):21- 25.
10. Nguyen CM, Beroukhim K, Danesh MJ, et al. The psychosocial impact of acne, vitiligo, and psoriasis: a review. Clin Cosmet Investig Dermatol. 2016;9:383-392.
11. Hester C, Park C, Chung J, et al. Medication adherence in children and adolescents with acne vulgaris in medicaid: A retrospective study analysis. Pediatr Dermatol. 2016;33(1):49-55.
12. Kraft J, Freiman A. Management of acne. Cmaj. 2011;183(7):E430-435.
13. Leyden J, Stein-Gold L, Weiss J. Why topical retinoids are mainstay of therapy for acne. Dermatol Ther (Heidelb). 2017;7(3):293-304.
14. Yeh L, Bonati LM, Silverberg NB. Topical retinoids for acne. Semin Cutan Med Surg. 2016;35(2):50-56.
15. Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol. 2008;9(6):369-381.
16. Tanghetti E, Draelos Z, Grimes P, et al. Moisturizer use enhances facial tolerability of tazarotene 0.1% cream without compromising efficacy in patients with acne vulgaris. Poster Presented at the 32nd Hawaii Dermatology Seminar. 2008.
17. Tanghetti EA, Stein Gold L, Del Rosso JQ, et al. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. J Dermatolog Treat. 2019:1-8.
18. Tanghetti EA, Kircik LH, Green LJ, et al. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris. J Drugs Dermatol. 2019;18(6):542-548.
19. Tanghetti EA, Werschler WP, Lain T, Guenin E. Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: Results from two phase 3 trials. J Drugs Dermatol. 2020;19(1).
20. Acne-specific Quality of Life questionnaire (Acne-QoL) manual & interpretation guide. 2003; (Uploaded-11-01-2019-20-05-40)-Study-related%20document.pdf Accessed December 6, 2019.
21. Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013;131 Suppl 3:S163-186.
22. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(5 Suppl):S1-50.
23. Leyden JJ, Tanghetti EA, Miller B, et al. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis. 2002;69(2 Suppl):12-19.
24. Webster GF, Guenther L, Poulin YP, et al. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002;69(2 Suppl):4-11.
25. Eichenfield LF, Sugarman JL, Guenin E, et al. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a preadolescent population. Pediatr Dermatol. 2019;36(2):193-199.
26. St Surin-Lord S, Schlesinger TE, Guenin E. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a preadolescent and adolescent population. J Clin Aesthet Dermatol. 2019;12(9):E57- e61.
27. Tanghetti E, Werschler WP, Lain E, et al. Novel polymeric lotion formulation of once-daily tazarotene (0.045%) for moderate-to-severe acne: Pooled phase 3 analysis. J Drugs Dermatol.


Lawrence F. Eichenfield MD